コンテンツへスキップ
Merck
すべての画像(1)

主要文書

GE17-5280-02

nProtein A Sepharose™ 4 Fast Flow

Cytiva 17-5280-02, pack of 200 mL

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

UNSPSCコード:
41106500
NACRES:
NA.56

ligand

native protein A (S. aureus)

包装

pack of 200 mL

メーカー／製品名

Cytiva 17-5280-02

保管条件

(20% Ehtanol)

Matrix

4% cross-linked agarose

平均直径

90 μm (d50v)

動作範囲

3-9

キャパシティ

>30 mg binding capacity(human IgG/ml)

適合性

suitable for bioprocess medium

保管温度

2-8°C

詳細

nProtein A Sepharose™ 4 Fast Flow is native protein A coupled to Sepharose™ 4 Fast Flow for the purification of monoclonal and polyclonal antibodies at both laboratory and process scale.

nProtein A Sepharose™ 4 Fast Flow is native protein A coupled to the well established Sepharose™ 4 Fast Flow base matrix. The native protein A ligand is produced by fermenting a selected strain of Staphylococcus aureus. The purified protein is coupled to the cross-linked 4% agarose base matrix by the cyanogen bromide technique, giving a highly stable medium with minimal non-specific adsorption. nProtein A Sepharose™ 4 Fast Flow is manufactured without using animal-derived components.

nProtein A Sepharose™ 4 Fast Flow has nearly twice the total IgG binding capacity of Protein A Sepharose™ CL-4B, and is suitable for recovery and purification of monoclonal antibodies from cell culture at both laboratory and process scale. nProtein A Sepharose™ 4 Fast Flow was developed and tested in co-operation with leading manufacturers of purified monoclonal antibody products, and is used in routine commercial production.

As member of the BioProcess media range, nProtein A Sepharose™ 4 Fast Flow meets industrial demands with security of supply and comprehensive technical and regulatory support.

特徴および利点

  • Replaces Protein A Sepharose™ 4 Fast Flow, the first Cytiva Protein A medium for large-scale purification of antibodies.
  • Used in routine commercial production of monoclonal antibodies
  • Free from animal-derived components.

アナリシスノート

この製品の分析証明書は、www.cytiva.com.

法的情報

Sepharose is a trademark of Cytiva

ピクトグラム

Flame
GHS02

シグナルワード

Warning

危険有害性情報

H226

保管分類コード

3 - Flammable liquids

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Monique G P van der Wijst et al.
Science translational medicine, 13(612), eabh2624-eabh2624 (2021-08-26)
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the prevalence of these antibodies, their longitudinal dynamics across
Caleigh Mandel-Brehm et al.
Annals of neurology, 92(2), 279-291 (2022-04-26)
Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation and Autonomic Dysregulation (ROHHAD), is a severe pediatric disorder of uncertain etiology resulting in hypothalamic dysfunction and frequent sudden death. Frequent co-occurrence of neuroblastic tumors have fueled suspicion of an autoimmune paraneoplastic neurological syndrome
Sara E Vazquez et al.
eLife, 9 (2020-05-16)
The identification of autoantigens remains a critical challenge for understanding and treating autoimmune diseases. Autoimmune polyendocrine syndrome type 1 (APS1), a rare monogenic form of autoimmunity, presents as widespread autoimmunity with T and B cell responses to multiple organs. Importantly
Paul Bastard et al.
Science immunology, eabp8966-eabp8966 (2022-07-21)
Life-threatening 'breakthrough' cases of critical COVID-19 are attributed to poor or waning antibody response to the SARS-CoV-2 vaccine in individuals already at risk. Pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in

資料

Purification Using Protein A-based Chromatography Media

This page shows various purification options for Protein A Sepharose chromatography media and describes typical binding and elution conditions for Protein A Sepharose chromatography media.

Immunoprecipitation Techniques

This page describes immunoprecipitation (immunoaffinity or pull-down techniques).

Column Packing and Preparation for Affinity Chromatography of Antibodies

This page describes efficient column packing and preparation for affinity chromatography of antibodies.

Desalting and Buffer Exchange for Affinity Chromatography of Antibodies

Desalting at laboratory scale is a well-proven, simple, and fast method that will rapidly remove low molecular weight contaminants at the same time as transferring the sample into the desired buffer in a single step.

プロトコル

Pull-down assays

This page provides information about different pull-down assays for the further isolation of multiprotein complexes to identify their components with products from Cytiva.

Protein A-Based Separation with Cytiva Products

Protein A, coupled to Sepharose, binds IgG via its Fc regions, facilitating affinity chromatography purification.

Performing a Purification of IgG Antibodies with Protein G Sepharose® 4 Fast Flow

This page shows how to separate IgG antibodies by affinity chromatography using Protein G Sepharose 4 Fast Flow from Cytiva.

Converting From Linear Flow (cm/hour) to Volumetric Flow Rates (mL/min) and Vice Versa

This page shows how to convert between linear flow and volumetric flow rates in affinity chromatography.

すべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）